Zwick, M.B., H.K. Komori, R.L. Stanfield, S. Church, M. Wang, P.W.H.I. Parren, R. Kunert, H. Katinger, I.A. Wilson and D.R. Burton . The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-HIV-1 antibody 2F5. J. Virol., 78: 3155-3161, 2004.
Burton, D.R. , R.C. Desrosiers, R.W. Doms, W.P. Koff, P.D. Kwong, J.P. Moore, G.P. Nabel, J. Sodroski, I.A. Wilson and R.P. Wyatt. HIV vaccine design and the neutralizing antibody problem. Nature Immunology , 5 :233-236, 2004.
Binley, J.M., T. Wrin, B. Korber, M.B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C.J. Petropoulos, D.R. Burton . A comprehensive cross-clade neutralization analysis of panel of anti-HIV-1 monoclonal antibodies. J. Virol., 78: 13232-13252 , 2004.
Burton, D.R. , R.C. Desrosiers, R.W. Doms, M.B. Feinberg, R.C. Gallo, M. Hahn, J.A. Hoxie, E. Hunter, B. Korber, A. Landay, M.M. Lederman, J. Lieberman, J.M. McCune, J.P. Moore, N. Nathanson, L. Picker, D. Richman, C. Rinaldo, M. Stevenson, D.I. Watkins, S.M. Wolinsky, J.A. Zack. A sound rationale needed for phase III HIV-1 vaccine trials. Science, 303 :316, 2004.
Pantophlet, R., I. Wilson and D.R. Burton . Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Engineering, Design and Selection , 17: 749-758, 2004.
Moore, J.P., D.R. Burton . Urgently needed: a flter for the HIV-1 vaccine pipeline. Nature Medicine, 10: 769-771, 2004.
Zwick, M.B., E.O. Saphire and D.R. Burton . gp41: The shy protein of HIV. Nature Medicine , 10:133-134, 2004.
Woof, J.M., D.R. Burton . Human antibody-Fc receptor interactions illuminated by crystal structures, Nat. Rev. Immunol., 4:89-99, 2004.